Engineered cell particles plus bone growth protein to boost bone healing in type 2 diabetes
Dual Delivery of Engineered EVs and Growth Factor for Bone Regeneration
Combining engineered stem-cell particles with a bone-growth protein to help adults with type 2 diabetes heal bone injuries more reliably.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11322611 on NIH RePORTER |
What this research studies
Researchers will combine extracellular vesicles (tiny particles) made from mesenchymal stem cells that carry anti-inflammatory microRNAs with recombinant human BMP-2, a bone growth protein, and deliver both using a gel-and-bead release system. First they will identify which vesicle microRNAs reduce inflammation and promote bone repair, then optimize the combined delivery materials and dosing. Experiments will use laboratory and preclinical models that mimic the healing problems seen in people with type 2 diabetes. The goal is to reduce inflammation-driven failure of bone repair and improve durable bone healing in diabetes.
Who could benefit from this research
Good fit: Adults with type 2 diabetes who have fractures, delayed healing, or nonunion bone injuries that impair recovery would be the most relevant candidates for this line of work.
Not a fit: People without bone-healing problems or those with active infection, uncontrolled medical conditions, or allergies to treatment components may not benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could improve bone healing, lower complication rates, and reduce the need for repeat surgeries in people with type 2 diabetes.
How similar studies have performed: Recombinant BMP-2 is already used clinically for bone repair and engineered MSC extracellular vesicles have shown promising preclinical immunomodulatory effects, making the combined delivery strategy relatively novel but grounded in prior work.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Kang, Miya — University of Illinois at Chicago
- Study coordinator: Kang, Miya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.